Provides the Centrellis AI platform for biopharma to accelerate drug discovery. Offers advanced sequencing services for research and clinical applications. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.6× for every dollar of annual revenue.
Analysts' average target sits 650% above today's price.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 19% a year on average.
Sales run at $427.5M a year. A small number, but proof the product has real buyers.
There is $171.3M in the vault; even if every debt were paid off, $110.8M would remain.
A loss of $21.0M against $427.5M in annual sales.
The stock sits at $0.31. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.